The increase in the chronic lower back pain market size is a direct consequence of the expected launch of potential therapies, along with great competition among various companies and precision approaches that will lead to more effective therapies.
LAS VEGAS, Sept. 21, 2023 /PRNewswire/ -- DelveInsight's Chronic Lower Back Pain Market Insights report includes a comprehensive understanding of current treatment practices, chronic lower back pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Chronic Lower Back Pain Market Report
- According to DelveInsight analysis, the chronic lower back pain market is anticipated to increase at a significant CAGR during the forecast period due to the expected launch of emerging therapies.
- According to DelveInsight's estimates, the total prevalent cases of CLBP in the 7MM was ~77 million in 2022. These cases of CLBP in the 7MM are expected to increase throughout the forecast period, i.e., 2023-2032.
- Leading chronic lower back pain companies such as Eli Lilly and Company, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, and others are developing novel chronic lower back pain drugs that can be available in the chronic lower back pain market in the coming years.
- Some key therapies for chronic lower back pain treatment include LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, and others.
- InFebruary 2023, Camurus withdrew the application for CAM2038 to include chronic pain.
- In February 2023, the FDA granted regenerative medicine advanced therapy (Rmat) designation to Rexlemestrocel-L for chronic lower back pain.
Discover which therapies are expected to grab the major chronic lower back pain market share @ Chronic Lower Back Pain Market Report
Chronic Lower Back Pain Overview
Chronic lower back pain is a prevalent and debilitating medical condition that affects millions of individuals worldwide. Unlike acute back pain, which typically resolves within a few weeks, chronic lower back pain persists for months or even years, significantly impacting a person's quality of life. This condition can have various causes, making its diagnosis and treatment complex. Chronic lower back pain can be attributed to several factors. The most common cause is musculoskeletal issues, such as herniated discs, spinal stenosis, or osteoarthritis, which result in persistent discomfort.
Individuals suffering from chronic lower back pain often experience a range of symptoms. These may include a persistent dull ache or sharp, shooting pain in the lower back region. Pain may radiate down into the legs, a phenomenon known as sciatica, and can be accompanied by muscle stiffness or weakness. Daily activities like walking, sitting, or lifting objects can become excruciating tasks for those with chronic lower back pain. Diagnosing the underlying cause of chronic lower back pain can be challenging due to its multifactorial nature. Typically, a healthcare provider will start with a comprehensive medical history and physical examination. Diagnostic imaging, such as X-rays, CT scans, or MRI scans, may be ordered to visualize the spine's structures and identify any abnormalities.
Chronic Lower Back Pain Epidemiology Segmentation
The chronic lower back pain epidemiology section provides insights into the historical and current chronic lower back pain patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The chronic lower back pain market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Total CLBP Prevalent Cases
- Total CLBP Diagnosed Prevalent Cases
- CLBP Gender-Specific Diagnosed Prevalent Cases
- CLBP Age-Specific Diagnosed Prevalent Cases
Chronic Lower Back Pain Treatment Market
CLBP is a complex process, and just as each patient has a highly personalized illness process, so does the treatment plan. There are various pharmaceutical classes, each with its own mechanism of action that can assist the practitioner in focusing on a specific element of a patient's pain. Furthermore, patient-specific characteristics are considered while establishing a regimen to ensure adherence and optimize outcomes.
Several essential principles must be considered by physicians before they can begin treating low back pain effectively. For starters, there is more information available on the usage of drugs for acute low back pain than chronic low back pain. This is not to say that specific pharmacologic drugs are ineffective in the treatment of persistent low back pain; rather, there is less data due to limitations in examining long term adverse effects. In particular, the pharmacological class and, in certain cases, the individual medicine chosen may be influenced by side effects and the intended mechanism of pain.
The bulk of low back pain is caused by a mechanical etiology, which includes a degenerative disc or joint disease, vertebral fracture, and deformities and affects up to 80-90% of patients, with neurogenic, inflammatory, and other less prevalent causes accounting for the remaining etiologies. The initial pharmacologic agents chosen must be targeted at the underlying cause. However, as the pain becomes chronic, a broader strategy is usually required due to the diminished efficacy of the targeted treatment. If the etiology of the low back pain is inflammatory, targeted therapy may include anti-inflammatory medication. In patients with rheumatoid arthritis or ankylosing spondylitis, this refers to the use of nonsteroidal anti-inflammatories (NSAIDs) and treatment with corticosteroids or disease-modifying antirheumatic medications (DMARDs) early in the disease's progression.
To know more about chronic lower back pain treatment, visit @ Chronic Lower Back Pain Treatment Drugs
Key Chronic Lower Back Pain Therapies and Companies
- LY3016859: Eli Lilly and Company
- Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
- Semdexa (SP-102): Scilex Holding
- Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
- AMG0103: AnGes MG, Inc
Learn more about the FDA-approved drugs for chronic lower back pain @ Drugs for Chronic Lower Back Pain Treatment
Chronic Lower Back Pain Market Dynamics
The dynamics of the chronic lower back pain market are undergoing significant shifts as healthcare systems and patient preferences evolve. One of the key drivers in this CLBP market is the growing aging population, as elderly individuals are more prone to experiencing chronic lower back pain. Additionally, the increasing prevalence of sedentary lifestyles and obesity contributes to the rising incidence of this condition. Medical advancements, including minimally invasive surgical procedures, are altering treatment approaches and improving patient outcomes.
Furthermore, the CLBP market is witnessing a surge in the demand for non-pharmacological interventions such as physical therapy, yoga, and chiropractic care as patients seek holistic approaches to managing their pain. With the rise of telemedicine and digital health solutions, remote monitoring and personalized treatment plans are becoming more accessible, transforming the way chronic lower back pain is managed. Overall, the chronic lower back pain market is characterized by a complex interplay of demographic trends, technological innovations, and shifting healthcare paradigms, all of which are shaping its current and future dynamics.
Despite the evolving dynamics, the chronic lower back pain market faces several formidable barriers that impact its trajectory. Firstly, there is a growing concern regarding the misuse and addiction potential of opioid-based pain medications, leading to stricter regulations and reduced access to these drugs for patients in need. Additionally, the high cost of advanced surgical interventions and innovative treatments can pose a significant barrier for many patients, especially in regions with limited healthcare coverage.
Furthermore, the fragmented nature of the healthcare system, varying insurance policies, and disparities in healthcare access can create inequities in the management of chronic lower back pain. Patients from disadvantaged backgrounds may struggle to access specialized care and alternative therapies, exacerbating the problem.
Lastly, the lack of standardized diagnostic tools and treatment protocols for chronic lower back pain can hinder effective management and result in trial-and-error approaches that extend patient suffering. Bridging these barriers will be essential to optimizing care and outcomes for those affected by this prevalent and debilitating condition.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Chronic Lower Back Pain Companies | Eli Lilly and Company, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, and others |
Key Chronic Lower Back Pain Therapies | LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, and others |
Scope of the Chronic Lower Back Pain Market Report
- Therapeutic Assessment: Chronic Lower Back Pain current marketed and emerging therapies
- Chronic Lower Back Pain Market Dynamics: Conjoint Analysis of Emerging Chronic Lower Back Pain Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Chronic Lower Back Pain Market Access and Reimbursement
Discover more about chronic lower back pain drugs in development @ Chronic Lower Back Pain Clinical Trials
Table of Contents
1. | Chronic Lower Back Pain Market Key Insights |
2. | Chronic Lower Back Pain Market Report Introduction |
3. | Chronic Lower Back Pain Market Overview at a Glance |
4. | Chronic Lower Back Pain Market Executive Summary |
5. | Disease Background and Overview |
6. | Chronic Lower Back Pain Treatment and Management |
7. | Chronic Lower Back Pain Epidemiology and Patient Population |
8. | Patient Journey |
9. | Chronic Lower Back Pain Marketed Drugs |
10. | Chronic Lower Back Pain Emerging Drugs |
11. | Seven Major Chronic Lower Back Pain Market Analysis |
12. | Chronic Lower Back Pain Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Chronic Lower Back Pain Pipeline
Chronic Lower Back Pain Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lower back pain companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, among others.
Chronic Lower Back Pain Epidemiology
Chronic Lower Back Pain Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical, and forecasted chronic lower back pain epidemiology in the 7MM.
Chronic Back Pain Pipeline
Chronic Back Pain Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic back pain companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, among others.
Ankylosing Spondylitis Pipeline
Ankylosing Spondylitis Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key ankylosing spondylitis companies, including Fresenius Kabi, Shanghai Henlius Biotech, Pfizer, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus Cadilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, UCB Biopharma, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934394.html
